miR-29a降低PIK3CA的表达,抑制宫癌细胞动态:一个比较的临床分析
Hyorim Jeong1, Kangchan Choi2,3, Dasom Hwang3
1College of Engineering and Medicine, University of Illinois Chicago, Chicago, IL 60612, USA.
Current issues in molecular biology
|November 26, 2024
概括
微RNA-29a (miR-29a) 有效地抑制子宫癌细胞中的PIK3CA瘤基因表达. 这种抑制减少了细胞分裂和迁移,为晚期宫癌提供了有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 宫癌查依赖于HPV/Pap检测,但晚期的结果不佳.
- 已知PIK3CA瘤基因表达是宫癌进展的驱动因素.
- 向瘤基因为晚期宫癌提供了潜在的治疗途径.
研究的目的:
- 研究微RNA-29a (miR-29a) 在抑制子宫癌中PIK3CA表达的治疗潜力.
- 评估miR-29a对宫癌细胞增殖和迁移的影响.
- 在临床样本中将miR-29a水平与疾病进展相关联.
主要方法:
- 用miR-29a感染宫癌细胞系 (SiHa,C33A,HeLa) 的情况.
- 通过RT-qPCR和Western blot量化PIK3CARNA和蛋白质水平.
- 伤口愈合和细胞迁移测试以评估细胞行为.
- 在患者活检样本中分析miR-29a度.
主要成果:
- 在RNA和蛋白质水平上,miR-29a转染显著降低了PIK3CA的表达.
- miR-29a抑制了HeLa细胞中的细胞分裂和迁移.
- miR-29a直接与PIK3CA的3'-UTR结合,对其表达进行下调.
- 较低的miR-29a度与晚期宫癌进展相关.
结论:
- 在宫癌中,miR-29a通过准PIK3CA作为瘤抑制剂.
- miR-29a显示出作为一种治疗剂的潜力,可以减缓子宫癌的进展,特别是在晚期.
- 用miR-29a准PIK3CA为宫癌治疗提供了一个新的策略.
相关概念视频
01:23Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:22MicroRNAs
21.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:19Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K